2017: Child Opioid Safety Rules

On This Day in Health: April 20, 2017

On April 20, 2017, the U.S. Food and Drug Administration announced stronger labeling restrictions for codeine and tramadol to protect children and breastfed infants. The action added contraindications and warnings to prescription products because of serious breathing risks. Codeine and tramadol were contraindicated in children younger than twelve, and tramadol received a further contraindication for pain after tonsil or adenoid removal in patients younger than eighteen. The announcement was a safety milestone rather than a new treatment approval. It reflected a revised understanding of how medicines already in use could cause severe harm in particular patient groups, even when the concern was not misuse or addiction.

The underlying problem involved differences in how the body metabolizes these drugs. Some people break them down unusually quickly, producing high levels of active opioid substances that can suppress breathing. For codeine, conversion to morphine is central to that risk. A dose prescribed with an ordinary expectation of effect can consequently behave very differently in a susceptible patient. Infants can also be exposed through breast milk when a nursing mother takes the medicine. The FDA strengthened its warning against use during breastfeeding because serious reactions in infants could include excessive sleepiness, difficulty feeding and breathing problems. These concerns made age and individual physiology important parts of evaluating safety.

The April changes built on earlier action. Since 2013, codeine labeling had already carried a boxed warning and a contraindication for postoperative pain following tonsil or adenoid removal in patients younger than eighteen. The 2017 decision added broader restrictions and brought a comparable postoperative contraindication to tramadol. It also warned against use of either medicine in adolescents aged twelve to eighteen who were obese or had obstructive sleep apnea, severe lung disease or other conditions that increased breathing risk. These were related but distinct provisions. Keeping the age groups and circumstances clear is necessary to describe what the agency actually changed on that date.

April 20 demonstrates that the evaluation of a medicine continues after it enters practice. Reports, biological understanding and evidence gathered over time can alter the terms under which a familiar product is considered appropriate. The FDA communicated the decision to clinicians and families through labeling changes and public safety information, recognizing that a warning only helps if it reaches the people making decisions. The anniversary is best understood as part of the continuing effort to make pediatric treatment safer while acknowledging that pain and cough still require appropriate care. It also separates this particular 2017 action from subsequent changes to opioid cough medicines. The event’s significance lies in translating a serious, unevenly distributed risk into more specific restrictions for vulnerable patients.